New Delhi: IIT Alumni Council announces fourth generation vaccine with ayurvedic adjuvant under MegaLab initiative.
“IIT Alumni Council announces India’s first antigen-free, novel vaccine which is self-limiting, locally manufactured and based on indigenous technology. The preservative-free vaccine is being coupled with an Ayurveda inspired adjuvant which will enhance safety as well as be highly efficacious. The end objective is to deliver a continuously upgradable vaccine which can outpace the virus thus helping to end the pandemic.” said Ravi Sharma, President of the IIT Alumni Council.
“We have made remarkable progress globally in understanding vaccines since August 2020. This has helped eliminate many of the vaccine modalities being investigated and we now know that a multi-pronged approach that will elicit an antibody response which neutralises a wide variety of virus mutants is the right target to pursue. Furthermore, the potential ability to access and build upon pate
May 14, 2021
It has sanctioned ₹300 crore from its Megafund initiative
The IIT Alumni Council has joined the race to develop a preventive vaccine for Covid-19, for which it has sanctioned an immediate ₹300 crore and expects to get an another ₹1,800 crore from its MegaFund initiative.
The vaccine stack – a two-dose vaccine which stops the spread of Covid-19 and prevents infection within a few days of the first dose – is said to be free of attenuated animal virus or deactivated Covid virus or virus fragments. The vaccine would be cold-chain preservation, a move that will further its reach to the key metros.
The IIT Alumni Council is the largest global body of alumni, students and faculty, spread across all the 23 IITs and partnering Technical Institutes of Excellence (TieNet).